Dishman Carbogen Amcis Ltd Falls to 52-Week Low of Rs.168

Stock Price Movement and Market Context

On 2 March 2026, Dishman Carbogen Amcis Ltd’s stock recorded an intraday low of Rs.168, representing a 4.03% decline on the day. This drop contributed to a two-day losing streak, during which the stock has fallen by 9.14%. The stock’s performance today notably underperformed the Pharmaceuticals & Biotechnology sector by 3.16%, signalling relative weakness within its industry peer group.

The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring the sustained bearish trend. In contrast, the Sensex, despite opening sharply lower by 2,743.46 points, managed a partial recovery and was trading at 79,692.55 points by midday, down 1.96%. The Sensex remains below its 50-day moving average, though the 50DMA is positioned above the 200DMA, indicating mixed signals for the broader market.

Long-Term Performance and Relative Comparison

Over the past year, Dishman Carbogen Amcis Ltd has delivered a negative return of 16.19%, significantly lagging behind the Sensex’s positive 8.87% gain over the same period. The stock’s 52-week high was Rs.321.15, highlighting the extent of the decline from its peak to the current low. Furthermore, the stock has underperformed the BSE500 index across multiple time frames, including the last three years, one year, and three months, indicating persistent underperformance relative to a broad market benchmark.

Financial Metrics and Fundamental Assessment

Dishman Carbogen Amcis Ltd’s financial indicators reveal several areas of concern. The company’s long-term fundamental strength is weak, with an average Return on Capital Employed (ROCE) of just 0.97%. This low ROCE suggests limited efficiency in generating returns from its capital base. Net sales have grown at a modest annual rate of 8.10% over the past five years, reflecting subdued growth in revenue generation.

Debt servicing capacity is also constrained, as evidenced by a high Debt to EBITDA ratio of 4.96 times. This elevated leverage ratio indicates significant debt relative to earnings before interest, taxes, depreciation, and amortisation, which may pressure the company’s financial flexibility.

Quarterly profitability metrics have deteriorated sharply. Profit Before Tax excluding Other Income (PBT less OI) stood at a loss of Rs.17.10 crore, a decline of 188.24% compared to the previous quarter. Similarly, the Profit After Tax (PAT) was negative Rs.12.97 crore, falling by 403.0%. The operating profit to interest coverage ratio is at a low 2.47 times, signalling limited cushion to meet interest obligations from operating profits.

Institutional Investor Activity

Institutional investors have reduced their holdings by 0.51% over the previous quarter, now collectively holding 8.93% of the company’s shares. This decline in institutional participation may reflect cautious sentiment among investors with greater analytical resources and insight into the company’s fundamentals.

Valuation and Peer Comparison

Despite the challenges, the stock’s valuation metrics indicate a very attractive price point. The company’s ROCE of 3.2 and an Enterprise Value to Capital Employed ratio of 0.6 suggest that the stock is trading at a discount relative to its capital base. Additionally, the stock’s price-to-earnings-growth (PEG) ratio stands at 0.1, which is low and typically indicative of undervaluation when compared to peers.

Over the past year, while the stock price has declined by 16.19%, the company’s profits have increased by 233.1%, highlighting a divergence between earnings growth and market valuation. This disparity may be a factor in the stock’s discounted trading levels relative to historical peer valuations.

Summary of Key Performance Indicators

Dishman Carbogen Amcis Ltd currently holds a Mojo Score of 17.0 and a Mojo Grade of Strong Sell, upgraded from a previous Sell rating on 12 January 2026. The company’s market capitalisation grade is 3, reflecting its mid-cap status within the Pharmaceuticals & Biotechnology sector.

The stock’s recent price action, combined with its financial metrics and institutional investor behaviour, paints a picture of a company facing multiple headwinds. The sustained decline to a 52-week low of Rs.168, coupled with underperformance relative to sector and market benchmarks, highlights the challenges the company is navigating in the current market environment.

While the valuation appears attractive on certain metrics, the overall financial profile and market performance have contributed to the stock’s current standing and rating.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today